 (JMed Genet 1995;32:697-700) 
Osteogenesis imperfecta type I is the mildest form of dominantly inherited brittle bone disease. ' Dermal fibroblasts from most affected subjects produce and secrete about half the normal amount of type I collagen.23 A growing body of evidence indicates that mutations that alter the expression of COLlAl, the gene that encodes the proacl (I) chain of type I collagen, are responsible for these synthetic alterations.? Most characterised mutations lead to allele specific reduction in steady state amounts of COLlAl mRNA in both the nucleus and cytoplasm of cell. 9 Although promoter mutations are recognised as a mechanism for altering levels of mRNA in a number of genetic disorders, their potential for causing OI type I has not been investigated. In this paper we report our mutational analysis of the 5 The causative mutation responsible for the phenotype was unknown in all. The COLlAl gene from each affected person had been previously screened by DGGE, using overlapping primer pairs that amplified 400 to 550 bp fragments of genomic DNA. In addition, about one-sixth of the gene had been screened by SSCP at the time of this analysis.
PCR AND MUTATION SCREENING
Aliquots of genomic DNA isolated either from white blood cells or from cultured dermal fibroblasts of affected subjects served as template for amplification by PCR.'0 The sequences ofthe oligonucleotides used as primers for PCR were derived from published sequence information" (figure). Amplification conditions were as previously described.'2 Four overlapping COLlAl domains, referred to as fragments A, B, C, and D (figure), were screened for mutations by denaturing gradient gel electrophoresis (DGGE)'3'4 or SSGP," 5'6 or both. For DGGE, which was performed on each fragment, the following linear gradients ofDNA denaturant (formamide and urea) were used: fragment A, 50-80%; fragment B, 35-65%; fragment C, 45-75%; fragment D, 55-80%.9 SSCP was performed on fragments A and D, as previously described,9 except that allele identification was by silver staining, using Typon Silver Sequence film (Promega, Madison, WI), rather than by autoradiography. Potential mutations were identified by direct sequence analysis of PCR amplified genomic DNA, using the dideoxy chain termination method. '" SEQUENCE ANALYSIS OF THE COLlAl PROMOTER Aliquots of amplified material from fragments B and C were electrophoresed in either 1 % LMP, or in 0.8% NuSieve (FMC Bioproducts, Rockland, ME), and the sole 486 bp and 489 bp bands, respectively, were excised from the gel. DNA fragments isolated in LMP were purified using the Promega Magic PCR Prep DNA Purification System; fragments isolated in NuSieve were used as templates without further purification. Sequence was determined by the dideoxy chain termination method. '7 Sequence ambiguities were clarified by analysis of both sense and antisense strands. For comparison, amplified genomic DNA from nine unrelated controls was also sequenced.
Results

ANALYSIS OF THE 5' END OF THE COLlAl GENE BY DGGE AND SSCP
We amplified four overlapping COLlAl fragments, which included 554 bp of 5' untranslated sequence, exon 1, and 65 bp of intron 1, from genomic DNA of 40 unrelated probands with OI type I. Fragment A spans from -434 to -187 of the COLlAl promoter (in the figure, the CAP site is labelled + 1), and overlaps with fragment B which includes promoter sequences -434 to + 52. Fragment C encompasses -204 to + 286, and includes portions of the COLlAl promoter, exon 1 (+120 to +221), and a small portion of the 5' end of intron 1, which flanks the exon. Fragments B and C both contain the CCAAAT and TATAAA boxes. Fragment C overlaps with fragment D, which spans from 0 to + 266, and includes the 5' CAP site, the sequence immediately upstream of the translation initiation site, exon 1, and 45 bp of intron 1. Each fragment was screened by DGGE for the presence of potential mutations; fragments A and D were also screened by SSCP.
Using this approach, we identified one person (referred to as proband 1) with an aberrant DGGE banding pattern in both fragments B and C. Direct sequence analysis of fragment C showed a G to A substitution located 9 bp downstream of the CCAAAT box, and a C to T transition 14 bp upstream of the TATAAA box (figure). Both were inherited from his unaffected father, whose dermal fibroblasts produced normal amounts of type I procollagen (data not shown). Another affected person (proband 2) had a variant SSCP conformer in fragment D. Direct sequence analysis of PCR products showed a G to A substitution at + 117, 3 bp upstream of the translation start site (figure). No additional sequence variants were identified in any of the other probands. DIRECT 
SEQUENCE ANALYSIS OF CCAAAT AND
TATAAA BOXES
To ensure that we had not overlooked a potential mutation in our screening, we performed direct sequence analysis on either fragment B or C. Sequence was obtained from -150 to + 1 (CAP site), which includes the CCAAAT and TATAAA boxes. There were no mutations in either of these regulatory sequences in any ofthe 40 affected people. In addition, except for the two substitutions noted above in proband 1, there were no deviations from the published sequence in this region, in any of the affected people, or in the nine controls.
Discussion
In most OI type I cell strains, COLlAl mRNA is derived primarily from one allele.8 Several different molecular mechanisms, which lead to allele specific decrease in COLlAl mRNA, have been identified in OI type I cell strains, including small deletions and insertions in exons that change the translational reading frame, and create new termination codons,912 point mutations that inactivate obligate splice sites,91819 and single nucleotide substitutions that lead to nonsense codons.9 Although mutations in the COLlAl promoter could also limit the amount of mRNA available from one COLlAl allele, none of the probands in this study has evidence of mutations in the promoter sequence analysed. The region screened encompasses the known regulatory motifs, including the TATAAA and CCAAAT boxes, and sequences that resemble viral enhancer elements, as well as exon 1 and a small portion of intron 1. Although intron 1 is known to contain enhancer elements,'1 we did not analyse these domains.
Our experience with mutation screening in OI type I cell strains indicates that mutation detection is optimised by using a combination of DGGE and SSCP, since some mutations will be detected by one, but not by the other technique.9 The only sequence variants found in proband 1 were initially identified by DGGE. We also sequenced portions of the COLlAl promoter, including the TATAAA and CCAAAT boxes, and did not identify additional sequence variants. Although the direct sequencing in this region confirmed the reliability of our approach to mutation detection in this region of the COLlAl gene, we cannot eliminate the possibility that mutations further upstream in the promoter could be responsible for OI type I.
There appears to be little variation from the published sequence in most of our probands. Although proband 1 had two sequence variants in the promoter, both were inherited from his unaffected father. In this family, the proband's mother has OI, but does not have the sequence variants. No family members were available to provide insight into the relevance of the substitution identified in proband 2. The substitution is located 3 bp upstream of the translation initiation site in an area that is thought to be important for ribosome recognition and binding.20 At the (-3) position, A is the most conserved nucleotide, followed by G, suggesting that the substitution in this person is unlikely to be of functional significance.
Mutations involving the TATAAA and CCAAAT boxes, as well as other nucleotides in the promoter region, have been identified in 1 thalassaemia and other haemoglobin- and two introns, the target for mutation is small, compared to large genes, such as dystrophin and the LDL receptor. Our own experience with the COLlAl gene supports this idea. We have identified 12 different COLlAl mutations that lead to a null allele in OI type I families, including four splicing mutations, two single nucleotide substitutions that create new termination codons, and six small deletions/insertions within exons9 (M C Willing, unpublished data). These data, in combination with the present study of the COLlAl promoter, suggest that most of the mutations responsible for OI type I will be in the coding portion of the gene.
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